CEBPD (CCAAT Enhancer Binding Protein Delta)

Mechanistically, its dynamic expression is strongly associated with the fibrotic cascade and inversely correlated with EMT progression as well as the expression of major extracellular matrix genes. These findings suggest that CEBPD may be a key regulatory factor in fibroid pathogenesis, offering a promising molecular target that warrants further functional validation in clinical management.

Immune microenvironment analysis showed distinct patterns of immune cell infiltration based on CEBPD expression levels. Overall, CEBPD significantly influences breast cancer progression and patient prognosis, suggesting its potential as a biomarker for therapeutic strategies.

Consistent with prior reports, our integrative genomic analyses and azacytidine treatment experiments further suggest a role for DNA methylation in downregulation of CEBPD expression during AML progression. Collectively, our results provide direct functional evidence for a tumor suppressor function of CEBPD in human cell lines and support prior studies implicating its epigenetic silencing in human AML.

These findings suggest that glioma CEBPD can contribute to immunosuppression by regulating miR-4257 and miR-3156, which target IL-12 in macrophages through sEV transmission. This research offers new insights into the relationship between glioma and immunosuppression, highlighting potential therapeutic avenues for enhancing anti-tumor immunity in GBM.

By targeting hypoxia-driven metabolic reprogramming, EGCG offers a dietary-based approach to modulate the CSC niche and potentially delay or prevent GBM progression. Moreover, the use of 3D spheroid models highlights their relevance in preclinical chemoprevention research, bridging the gap between simplistic 2D cultures and the complex biology of solid tumors.

Consistent with a previous report, our genomics analyses and azacytidine treatment experiments suggested a role for DNA methylation in downregulation of CEBPD expression during AML pathogenesis. Altogether, our results provide experimental evidence for a tumor suppressor function of CEBPD in AML.

By promoting T cell exhaustion and immunosuppressive signaling, particularly via localized TGF-β, these spatially segregated macrophages undermine treatment efficacy. Targeting APOE+ macrophages, especially in conjunction with ICB, presents a promising strategy to overcome immune resistance and enhance outcomes for ccRCC patients.

TMEM71 is an independent prognostic indicator for LGG and is strongly associated with the growth of LGG cells, positioning it as a potential novel target for treatment.

Besides, WTAP overexpression reversed the suppressive effect of CEBPD knockdown on GSCs stemnness, growth, migration and glycolysis in vitro, as well as the reducing effect on tumorigenicity of GSCs in vivo. CEBPD/WTAP axis played a vital role in regulating GSCs function, providing a potential therapy target for GBM.

We confirmed the potential importance of cell cycle-mediated regulation of C/EBPδ by showing that four of the most potent C/EBPδ activators-R547, PHA793387, AZD5438 and AT7519, all multi-cyclin-dependent kinase (CDK) inhibitors-limited the clonal expansion of PDAC cells. Next to providing a valuable selection of C/EBPδ-modulating compounds for the use in preclinical studies, this report contributes to our understanding of the molecular regulatory mechanisms of C/EBPδ in general and in PDAC in particular.

Furthermore, MKX upregulated SESN3 and downregulated BCL2L11, which may together underlie decreased etoposide-induced apoptosis...Taken together, our study identified MKX as novel aberrantly expressed homeobox gene in AML and MM, highlighting the function of IRX1 in normal myelopoiesis and B-cell development, and of IRX-related genes in corresponding malignancies. Our data merit further investigation of MKX and its deregulated target genes to serve as novel markers and/or potential therapeutic targets in AML patient subsets.

In conclusion, our study revealed that fibroblast recruitment and differentiation, as well as copy number loss at chromosome 6p, were associated with a higher degree of malignancy and immune dysfunction in HCC. The current discoveries provided new insights into the clinical treatment and diagnosis of HCC.